Starpharma Holdings Ltd. ADR | |
Stock Exchange | Other OTC |
EPS |
$0.23 |
Market Cap |
$360.17 M |
Shares Outstanding |
37.17 M |
Public Float |
- |
Starpharma Holdings Ltd. | |
Stock Exchange | Australian Stock Exchange |
EPS |
AUD0.03 |
Market Cap |
AUD516.66 M |
Shares Outstanding |
371.69 M |
Public Float |
341.99 M |
Starpharma Holdings Ltd. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
370.54 M |
Public Float |
- |
Address |
4-6 Southampton Crescent Abbotsford Victoria (VIC) 3067 Australia |
Employees | - |
Website | http://www.starpharma.com |
Updated | 07/08/2019 |
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. |